Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer

Publisher： Karger

E-ISSN： 1423-0232|60|1|19-23

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.1, 2000-12, pp. : 19-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum

By  

Oncology Research and Treatment, Vol. 27, Iss. 1, 2004-03 ,pp. : 58-64

Karger

Access to resources Recommend Favorite

Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 177-184

Karger

Access to resources Recommend Favorite

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

By  

Oncology, Vol. 67, Iss. 5-6, 2005-02 ,pp. : 376-381

Karger

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents

By  

Oncology, Vol. 84, Iss. 3, 2012-12 ,pp. : 158-165

Karger

Access to resources Recommend Favorite